Mitchell Lawrence Jones - 06 Oct 2026 Form 4 Insider Report for PALISADE BIO, INC. (PALI)

Reporting relationship: President & Chief Medical Officer
Issuer ticker: PALI
Reported as of: 06 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Oct 2026, 21:35:02 UTC
Prior SEC filing: 08 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Ryker Willie, Attorney-in-Fact for Mitchell Lawrence Jones

Key filing fact

Mitchell Lawrence Jones filed Form 4 for PALISADE BIO, INC. (PALI) on 07 Oct 2026.

Key facts

This page summarizes Mitchell Lawrence Jones's Form 4 filing for PALISADE BIO, INC. (PALI).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 07 Oct 2026, 21:35.

Change

Previous filing in this sequence was filed on 08 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001993292 Primary reporting owner

Jones Mitchell Lawrence

Relationship: President & Chief Medical Officer
Address: C/O PALISADE BIO, INC., 4600 SOUTH SYRACUSE STREET, SUITE 900, DENVER
Signature: /s/ Ryker Willie, Attorney-in-Fact for Mitchell Lawrence Jones
Signature date: 07 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PALI transaction

Common Stock

Options Exercise

Transaction value
Shares: +2,620,850
Change %: +2788%
Price
Shares after: 2,714,859
Date: 06 Oct 2026
Ownership: Direct
Footnotes: F1

PALI transaction

Common Stock

Tax liability

Transaction value
Shares: -1,031,102
Change %: -38%
Price: $1.49^*
Shares after: 1,683,757
Date: 06 Oct 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PALI transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -2,555,266
Change %: -33%
Price: $0.000000^*
Shares after: 5,110,534
Date: 06 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,555,266
Exercise price
Footnotes: F3, F4

PALI transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -65,584
Change %: -10%
Price: $0.000000^*
Shares after: 590,249
Date: 06 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 65,584
Exercise price
Footnotes: F3, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

Footnote F2

Represents the number of shares of common stock the Issuer has withheld to satisfy the Reporting Person's income tax withholding and remittance obligations as part of the settlement of vested RSUs. Accordingly, no shares of common stock will be sold in the public market to satisfy such income tax withholding and remittance obligations associated with the settlement of these vested RSUs.

Footnote F3

Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Footnote F4

The RSUs shall vest with respect to 1/3rd of the shares on October 6, 2026 and quarterly thereafter over the following eight quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

Footnote F5

The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following ten quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

SEC remarks

President & Chief Medical Officer